Clinical Trial: ENA-001 for Opioid Induced Respiratory Depression

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06967259) titled 'ENA-001 for Opioid Induced Respiratory Depression' on March 14.

Brief Summary: This study is a Phase I clinical trial to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles with single intravenous (IV) and intramuscular (IM) doses of ENA-001.

Study Start Date: June 03

Study Type: INTERVENTIONAL

Condition: Respiratory Depression

Intervention: DRUG: ENA-001

Concentration for ENA-001 IV formulation is 10 mg/mL. Concentration for ENA 001 IM formulation is 30 mg/mL.

DRUG: Placebo Comparator

Placebo comes in 5 mL/vial. Placebo matches ENA-001 injection; however, no ENA-001 is included.

Recr...